A new nutraceutical (Livogen Plus®) improves liver steatosis in adults with non-alcoholic fatty liver disease

Новый нутрацевтик (Livogen Plus®) улучшает стеатоз печени у взрослых с неалкогольной жировой болезнью печени
Yvelise Ferro, Roberta Pujia, Elisa Mazza, Lidia Lascala, Oscar Lodari, Samantha Maurotti, Arturo Pujia, Tiziana Montalcini
2022-08-19

CAP scoreLivogen Pluscontrolled randomized clinical trialliver steatosisnon-alcoholic fatty liver disease
BACKGROUND: Currently, there is no approved medication for non-alcoholic fatty liver disease management. Pre-clinical and clinical studies showed that several bioactive molecules in plants or foods (i.e., curcumin complex, bergamot polyphenol fraction, artichoke leaf extract, black seed oil, concentrate fish oil, picroliv root, glutathione, S-adenosyl-L-methionine and other natural ingredients) have been associated with improved fatty liver disease. Starting from these evidences, our purpose was to evaluate the effects of a novel combination of abovementioned nutraceuticals as a treatment for adults with fatty liver disease. METHODS: A total of 140 participants with liver steatosis were enrolled in a randomized, double-blind, placebo controlled clinical trial. The intervention group received six softgel capsules daily of a nutraceutical (namely Livogen Plus®) containing a combination of natural bioactive components for 12 weeks. The control group received six softgel capsules daily of a placebo containing maltodextrin for 12 weeks. The primary outcome measure was the change in liver fat content (CAP score). CAP score, by transient elastography, serum glucose, lipids, transaminases, and cytokines were measured at baseline and after intervention. RESULTS: After adjustment for confounding variables (i.e., CAP score and triglyceride at baseline, and changes of serum γGT, and vegetable and animal proteins, cholesterol intake at the follow-up), we found a greater CAP score reduction in the nutraceutical group rather than placebo (- 34 ± 5 dB/m vs. - 20 ± 5 dB/m, respectively; p = 0.045). The CAP score reduction (%) was even greater in those with aged 60 or less, low baseline HDL-C, AST reduction as well as in men. CONCLUSION: Our results showed that a new combination of bioactive molecules as nutraceutical was safe and effective in reducing liver fat content over 12 weeks in individuals with hepatic steatosis. Trial registration ISRCTN, ISRCTN70887063. Registered 03 August 2021-retrospectively registered, https://doi.org/10.1186/ISRCTN70887063.
1
A 12-week randomized, double-blind, placebo-controlled trial tested Livogen Plus®, a combination nutraceutical, in 140 adults with liver steatosis.
2
CAP score percentage reduction with Livogen Plus® was larger in subgroups: participants aged ≤60, those with low baseline HDL-C, men, and those with AST reduction.
3
Livogen Plus® produced a greater reduction in CAP score than placebo after adjustment: -34 ± 5 dB/m vs. -20 ± 5 dB/m (p = 0.045).
4
Primary outcomes included transient elastography CAP score and secondary measures included serum glucose, lipids, transaminases, and cytokines.
5
The nutraceutical was reported as safe and effective in reducing liver fat content over 12 weeks.

Adults with non-alcoholic fatty liver disease receiving the nutraceutical Livogen Plus® (vs placebo) in a randomized clinical trial

Effect of the Livogen Plus® nutraceutical on liver steatosis quantified by change in liver fat content (CAP score) and related biochemical markers over 12 weeks

Publication Details
Publication Date
2022-08-19
Journal
Publisher
ISSN
Cited by
30
Access Type
Author Information
Authors
Yvelise Ferro
Roberta Pujia
Elisa Mazza
Lidia Lascala
Oscar Lodari
Samantha Maurotti
Arturo Pujia
Tiziana Montalcini
Explore further
Open the scid.ai AI chat with a ready-made request: it will find papers on a similar topic and help build a literature review.
Find similar papers in the chat →
Make a presentation
100%